An examination of Alzheimer's disease case definitions using Medicare claims and survey data
- 3 May 2010
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 6 (4), 334-341
- https://doi.org/10.1016/j.jalz.2009.09.001
Abstract
The prevalence and expenditure estimates of Alzheimer's disease (AD) from studies using one data source to define cases vary widely. The objectives of this study were to assess agreement between AD case definitions classified with Medicare claims and survey data and to provide insight into causes of widely varied expenditure estimates.Data were obtained from the 1999-2004 Medicare Current Beneficiary Survey linked with Medicare claims (n = 57,669). Individuals with AD were identified by survey, diagnosis, use of an AD prescription medicine, or some combination thereof. We also explored how much health care and drug expenditures vary by AD case definition.The prevalence of AD differed significantly by case definition. Using survey report alone yielded more cases (n = 1,994 or 3.46%) than diagnosis codes alone (n = 1,589 or 2.76%) or Alzheimer's medication use alone (n = 1,160 or 2.01%). Agreement between case definitions was low, with kappa coefficients ranging from 0.37 to 0.40. Per capita health expenditures ranged from $16,547 to $24,937, and drug expenditures ranged from $2,303 to $3,519, depending on how AD was defined.Different information sources yield widely varied prevalence and expenditure estimates. Although claims data provided a more objective means for identifying AD cases, survey report identified more cases, and pharmacy data also are an important source for case ascertainment. Using any single source will underestimate the prevalence and associated cost of AD. The wide range of AD cases identified by using different data sources demands caution interpreting cost-of-illness studies using single data sources.Keywords
Funding Information
- GlaxoSmithKline
This publication has 27 references indexed in Scilit:
- Alzheimer Disease in the US PopulationArchives of Neurology, 2003
- The Public Health Impact of Alzheimer's Disease, 2000–2050: Potential Implication of Treatment AdvancesAnnual Review of Public Health, 2002
- Alzheimer’s disease and related dementias increase costs of comorbidities in managed MedicareNeurology, 2002
- How Much Do Persons with Alzheimer's Disease Cost Medicare?Journal of the American Geriatrics Society, 2000
- Cost of Alzheimer's Disease and Related Dementia in Managed‐MedicareJournal of the American Geriatrics Society, 1999
- Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.American Journal of Public Health, 1998
- Alzheimer's Disease Under Managed Care: Implications from Medicare Utilization and Expenditure PatternsJournal of the American Geriatrics Society, 1998
- Estimated Prevalence of Alzheimer's Disease in the United StatesThe Milbank Quarterly, 1990
- Prevalence of Alzheimer's Disease in a Community Population of Older PersonsJAMA, 1989
- Alzheimer's DiseaseNew England Journal of Medicine, 1986